How Antibiotic Resistance Research Turns Surveillance Data Into Targets

Antibiotic resistance research starts from measurement. The WHO's Global Antimicrobial Resistance and Use Surveillance System reported in October 2025 that one in six laboratory-confirmed bacterial infections worldwide in 2023 was resistant to antibiotic treatment, per the WHO's news release. Research in the field converts surveillance signal into mechanisms, targets, and clinical candidates.

What does surveillance actually measure?

GLASS collects, standardizes, and shares national data on resistance in samples collected routinely for clinical purposes, and its 2025 report presented adjusted global and regional prevalence estimates for 93 infection type, pathogen, and antibiotic combinations, drawing on more than 23 million bacteriologically confirmed cases of bloodstream infections, urinary tract infections, gastrointestinal infections, and urogenital gonorrhoea, per the report's publication page. Data came from 104 countries in 2023 and 110 countries across 2016 to 2023.

The trend figures are the research community's baseline. Between 2018 and 2023, resistance rose in over 40% of the pathogen-antibiotic combinations monitored, with an average annual increase of 5% to 15%, according to the WHO release. The report covers eight common bacterial pathogens, including Acinetobacter species, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae, Staphylococcus aureus, and Streptococcus pneumoniae, each linked to one or more of the monitored infection types.

Geography is itself a finding. Resistance is highest in the WHO South-East Asia and Eastern Mediterranean regions, where one in three reported infections was resistant, and one in five in the African Region, per the WHO. Those gradients direct both research attention and public health spending toward the settings where empiric therapy fails most often.

How does a resistance measurement become a research question?

The bridge is the resistance mechanism. A surveillance line that says a Klebsiella isolate is resistant to carbapenems implies a molecular cause, a carbapenemase enzyme, a porin change, or an efflux pump, and each mechanism is a potential drug target. The standard research translation runs as follows:

1. Phenotype. Surveillance laboratories classify isolates as resistant or susceptible using standardized susceptibility testing, the data GLASS aggregates.
2. Genotype. Sequencing of resistant isolates identifies the genes and mutations associated with the phenotype, separating known mechanisms from unexplained resistance.
3. Mechanism. Biochemical and structural work establishes how a resistance determinant functions, for example which enzyme degrades which antibiotic class.
4. Target. Compounds are sought that inhibit the mechanism, restore susceptibility of existing antibiotics, or kill by a route the mechanism does not touch.
5. Candidate. Hits advance through the ordinary preclinical and clinical pipeline, where most of them fail for reasons unrelated to resistance.

Each stage depends on the one before it, which is why surveillance quality is a research input, not merely a report card. The GLASS report introduces a scoring framework to assess the completeness of national data, an acknowledgment that estimates are only as strong as the reporting systems beneath them.

What are the main resistance mechanisms researchers work against?

Four families of mechanism account for most clinical resistance, and each defines a research strategy. Degrading enzymes, the beta-lactamases and their many variants, chemically destroy antibiotic molecules before they reach their targets; the research response is inhibitor combinations that protect the antibiotic, and surveillance's rising carbapenem resistance figures track exactly this arms race. Efflux pumps expel drug molecules from the bacterial cell, and pump inhibitors have been a long, largely unrewarded research target. Target modification changes the bacterial molecule a drug binds, as happens with mutations in ribosomal components or penicillin-binding proteins, and forces chemists to redesign around the new shape. Finally, reduced permeability, porin loss and membrane changes, lowers intracellular drug concentration below effective thresholds, and it frequently acts in combination with the other mechanisms rather than alone.

Two properties make this target landscape hostile. The determinants are often mobile, carried on plasmids and transposons that move between bacterial species, so a mechanism selected in one pathogen can appear in another, which is why surveillance aggregates across eight common pathogens rather than studying any one. And resistance mechanisms typically carry only a small fitness cost, so they persist even when the selecting antibiotic is withdrawn, which is why stewardship slows resistance but rarely reverses it.

The mechanistic map also explains where non-traditional approaches fit. Bacteriophage therapy, anti-virulence compounds that disarm rather than kill, and narrow-spectrum agents guided by rapid diagnostics each try to sidestep the selection pressure that a broad-spectrum kill imposes, and all of them depend on knowing which mechanism, in which pathogen, in which patient population, they are being aimed at.

Why is the antibiotic pipeline structurally difficult?

The scientific and commercial obstacles reinforce each other. Scientifically, resistance mechanisms are diverse and transferable, moving between bacteria on mobile genetic elements, so a drug that defeats one mechanism faces selection pressure to be circumvented by the next. The WHO's finding that resistance rose in over 40% of monitored combinations in five years is a direct measure of how fast that selection operates at population scale.

Commercially, the newest antibiotics are deliberately conserved, which suppresses the volume that would reward development spending, a mismatch between public health value and revenue that the field has documented for years. The consequence is that much of the current research effort is aimed at stewardship-preserving strategies: narrow-spectrum agents matched to diagnostics, combination regimens that protect existing drugs, and non-traditional approaches such as bacteriophages and anti-virulence compounds.

Surveillance data also set priorities here. Pathogen-antibiotic combinations with high and rising resistance, and infections where empiric failure is dangerous, such as bloodstream infections, attract the most attention, which is consistent with the WHO report's focus on bloodstream, urinary, gastrointestinal, and gonococcal infections as its monitored categories.

What does the surveillance-to-clinic gap look like in practice?

Even a well-validated target takes years to reach patients, and the pipeline's attrition is unhidden. A mechanism characterized today defines a discovery program whose first clinical candidate might arrive years later, with registration further out, by which time the resistance landscape measured by GLASS will have shifted again. The 2018 to 2023 trend data make the point quantitatively: the problem being solved moves on the same timescale as the solving.

For readers evaluating resistance research claims, the checklist is short. Ask what was measured, in which pathogens and populations, and with what comparator: resistance is always relative to a specific drug or class, not a general property. Ask whether an effect shown in isolates or animal models has any clinical correlate. And ask where the data came from, because a finding built on surveillance from one region may not transfer to another with a different resistance profile.

The field's honest self-description is a race between measurement and mitigation. GLASS and its national counterparts have made the measurement genuinely global, with more than a hundred countries reporting; the mitigation side, targets converted into registered medicines, remains slow, uncertain, and badly distributed relative to the burden the surveillance system now quantifies each year.

For researchers, the practical opportunity in that asymmetry is directional. Surveillance now identifies, with annual granularity, which pathogen-antibiotic combinations are deteriorating fastest and in which regions, which is effectively a prioritized list of unmet need updated every October when the WHO report lands. Laboratories choosing discovery programs, funders allocating calls, and diagnostics companies selecting panels can all read the same table and point their work at the combinations where empiric therapy is failing most quickly. The dataset does not make the pipeline faster, but it removes the excuse for aiming it anywhere other than where the resistance actually is.